Woodstock Corp trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,570 shares of the medical research company’s stock after selling 700 shares during the quarter. Woodstock Corp’s holdings in Amgen were worth $1,476,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. TrimTabs Asset Management LLC grew its position in shares of Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after purchasing an additional 288 shares during the last quarter. Alpha Omega Wealth Management LLC grew its position in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after purchasing an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. grew its position in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after purchasing an additional 4 shares during the last quarter. American Beacon Advisors Inc. acquired a new stake in shares of Amgen in the first quarter valued at about $106,000. Finally, Nelson Roberts Investment Advisors LLC acquired a new stake in shares of Amgen in the first quarter valued at about $121,000. 78.10% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Inc. (NASDAQ AMGN) traded down 1.39% on Thursday, hitting $185.96. 2,734,976 shares of the stock were exchanged. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $191.10. The company has a market capitalization of $135.69 billion, a PE ratio of 16.94 and a beta of 1.36. The company has a 50-day moving average price of $180.38 and a 200 day moving average price of $169.99.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the prior year, the business posted $2.84 EPS. The business’s revenue was up 2.1% compared to the same quarter last year. Analysts anticipate that Amgen Inc. will post $12.57 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were given a dividend of $1.15 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.44%. Amgen’s payout ratio is presently 41.93%.

AMGN has been the topic of several research analyst reports. Cann reaffirmed a “buy” rating on shares of Amgen in a research report on Monday, August 28th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $203.00 price target on shares of Amgen in a research report on Thursday, September 7th. Deutsche Bank AG initiated coverage on Amgen in a research report on Friday, June 23rd. They issued a “hold” rating and a $172.00 price target on the stock. William Blair reaffirmed a “market perform” rating on shares of Amgen in a research report on Monday, June 26th. Finally, Mizuho reaffirmed a “buy” rating and issued a $198.00 price target (up from $183.00) on shares of Amgen in a research report on Thursday, September 28th. Ten analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $189.35.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/05/woodstock-corp-has-1-48-million-holdings-in-amgen-inc-amgn.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.